MIRM NASDAQ
Mirum Pharmaceuticals, Inc.
1W: -7.5%
1M: -16.9%
3M: -32.0%
YTD: +6.2%
1Y: +13.6%
3Y: +169.2%
5Y: +348.5%
$82.93
-0.99 (-1.18%)
Weekly Expected Move ±5.0%
$75
$79
$83
$87
$91
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships11
As Filer
counterparties named
2
As Counterparty
mentioned by others
5
Rel. Types
2021-11-19
Earliest Filing
2026-01-26
Latest Filing
target: 4
partner: 3
acquirer: 2
investor: 1
customer: 1
Counterparties (Filed by MIRM)
11 relationshipsCompanies named in MIRM's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Bluejay Therapeutics, Inc. | — | target | Target company acquired in a merger transaction | 2026-01-26 | View |
| Fortis Advisors LLC | — | partner | Representative and agent for Target security holders | 2026-01-26 | View |
| Bluejay Therapeutics, Inc. | — | target | Target company in the Merger Agreement to be acquired by Mirum Pharmaceuticals, Inc. | 2025-12-08 | View |
| Fortis Advisors LLC | — | investor | Representative, agent, and attorney in fact for the Target security holders in the Merger Agreement. | 2025-12-08 | View |
| Travere Therapeutics, Inc. | TVTX | target | Target of asset acquisition for Chenodal and Cholbam products | 2023-09-05 | View |
| Mirum Pharmaceuticals, Inc. | MIRM | acquirer | Acquired Travere Therapeutics assets and completed private placement with PIPE Investors | 2023-09-05 | View |
| Travere Therapeutics, Inc. | TVTX | target | Mirum Pharmaceuticals agreed to purchase substantially all assets related to Chenodal and Cholbam for up to $445 million | 2023-07-17 | View |
| Janssen Biotech, Inc. | — | customer | Purchased Mirum Pharmaceuticals' Rare Pediatric Disease Priority Review Voucher for $110.0 million. | 2021-12-22 | View |
| Johnson & Johnson | JNJ | partner | Parent company of Janssen Biotech, Inc., the buyer of the PRV. | 2021-12-22 | View |
| Janssen Biotech, Inc. | — | acquirer | Agreement to purchase Rare Pediatric Disease Priority Review Voucher for $110.0 million | 2021-11-19 | View |
| Johnson & Johnson | JNJ | partner | Parent company of Janssen Biotech, Inc. | 2021-11-19 | View |
Mentioned As Counterparty
2 mentionsOther companies that named MIRM in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| RNTX AILERON THERAPEUTICS INC | partner | Company on whose board of directors William C. Fairey serves. | 2023-10-31 | View |
| TVTX Travere Therapeutics, Inc. | target | Acquired substantially all assets related to Chenodal and Cholbam from Travere Therapeutics, Inc. | 2023-09-05 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Other Events | View | |
| 2026-09-08 | Officer/Director Change | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-05-18 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-05-04 | Other Events | View | |
| 2026-04-27 | Other Events | View | |
| 2026-04-08 | Exhibits | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-26 | Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure; Other Events; Financia | Acquisition | View |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-19 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-12-19 | Other Events | View | |
| 2025-12-08 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-11-17 | Other Events | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-30 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR